ロード中...
Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir
Background. Specific antiretroviral therapy (ART) medications and the severity of human immunodeficiency virus (HIV) disease before treatment contribute to bone mineral density (BMD) loss after ART initiation. Methods. We compared the percentage change in BMD over 96 weeks in 328 HIV-infected, treat...
保存先:
| フォーマット: | 論文 |
|---|---|
| 言語: | en |
| 出版事項: |
Oxford University Press
2015
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4577040/ https://ncbi.nlm.nih.gov/pubmed/25948863 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/infdis/jiv194 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|